Next Article in Journal
Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Relapsed and Refractory Mantle Cell Lymphoma
Previous Article in Journal
The Impact of Seasonal Operating Room Closures on Wait Times for Oral Cancer Surgery
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer

British Columbia Cancer Agency, Vancouver Centre, Vancouver, BC, Canada
CHUM, Montreal, QC, Canada
William Osler Health System, University of Toronto, Toronto, ON, Canada
IUCPQ-Université Laval, Québec City, QC, Canada
McMaster University, Juravinski Cancer Centre, Chair of Medical Advisory Committee, Lung Cancer Canada, Hamilton, ON, Canada
University Health Network, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada
University of Ottawa/Ottawa Hospital Research Institute/President Lung Cancer Canada, Ottawa, ON, Canada
Queen Elizabeth II Health Sciences Centre/Dalhousie University, Halifax, NS, Canada
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(1), 73-82;
Submission received: 3 November 2017 / Revised: 8 December 2017 / Accepted: 11 January 2018 / Published: 1 February 2018


Background: The development and approval of both targeted and immune therapies for patients with advanced non-small cell lung cancer (NSCLS) has significantly improved patient survival rates and quality of life. Biomarker testing for patients newly diagnosed with NSCLS, as well as for patients progressing after treatment with epidermal growth factor receptor (EGFR) inhibitors, is the standard of care in Canada and many parts of the world. Methods: A group of thoracic oncology experts in the field of thoracic oncology met to describe the standard for biomarker testing for lung cancer in the Canadian context, focusing on evidence-based recommendations for standard-of-care testing for EGFR, anaplastic lymphoma kinase (ALK), ROS1, BRAF V600 and programmed death-ligand (PD-L1) at the time of diagnosis of advanced disease and EGFR T790M upon progression. As well, additional exploratory molecules and targets are likely to impact future patient care, including MET exon 14 skipping mutations and whole gene amplification, RET translocations, HER2 (ERBB2) mutations, NTRK, RAS (KRAS and NRAS), as well as TP53. Results: The standard of care must include the incorporation of testing for novel biomarkers as they become available, as it will be difficult for national guidelines to keep pace with technological advances in this area. Conclusions: Canadian patients with NSCLS should be treated equally; the minimum standard of care is defined in this paper.
Keywords: biomarker testing; lung cancer; EGFR; ALK; ROS1; BRAF V600X; MET; PD-L1; Canada biomarker testing; lung cancer; EGFR; ALK; ROS1; BRAF V600X; MET; PD-L1; Canada

Share and Cite

MDPI and ACS Style

Melosky, B.; Blais, N.; Cheema, P.; Couture, C.; Juergens, R.; Kamel-Reid, S.; Tsao, M.-S.; Wheatley-Price, P.; Xu, Z.; Ionescu, D.N. Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer. Curr. Oncol. 2018, 25, 73-82.

AMA Style

Melosky B, Blais N, Cheema P, Couture C, Juergens R, Kamel-Reid S, Tsao M-S, Wheatley-Price P, Xu Z, Ionescu DN. Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer. Current Oncology. 2018; 25(1):73-82.

Chicago/Turabian Style

Melosky, B., N. Blais, P. Cheema, C. Couture, R. Juergens, S. Kamel-Reid, M.-S. Tsao, P. Wheatley-Price, Z. Xu, and D.N. Ionescu. 2018. "Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer" Current Oncology 25, no. 1: 73-82.

Article Metrics

Back to TopTop